最近，网络上流传着各种有关抗病毒药物瑞德西韦临床试验的消息，包括“药物短时间内已在761位患者身上全部显效”等说法甚多，一时间令网友感到困惑。

Rumors began spreading online Thursday evening saying the US drug remdesivir had achieved a remarkable effect on 761 patients participating in the first day of the drug's clinical trial.

瑞德西韦是什么？什么时候进行的试验？什么时候又能投入到使用中？伴随着相关消息而来的则是大家的一连串疑问。

对此，中日友好医院副院长曹彬教授于2月6日表示，有关瑞德西韦已经通过临床试验的说法不实：临床研究今天才开始，怎么可能知道结果？

Cao Bin, vice-president of China-Japan Friendship Hospital and a scientist in charge of the research, said trials have only just started at a hospital in Wuhan, Hubei province, and no results have been achieved yet.


 
据新华网2月5日报道，在科技部、国家卫健委、国家药监局等多部门支持下，抗病毒药物瑞德西韦（remdesivir）已完成临床试验的注册审批工作，第一批病例入组工作也已就位。首批新型冠状病毒感染的肺炎重症患者2月6日接受用药。

The registration for clinical trials on the antiviral drug Remdesivir has been approved, and the first batch of pneumonia patients infected by the novel coronavirus (2019-nCoV) are expected to start taking the drug on Thursday, according to an official conference Wednesday. The approval is jointly supported by the Ministry of Science and Technology (MOST), the National Health Commission and the National Medical Products Administration.


2月5日，瑞德西韦临床试验项目负责人、中日友好医院副院长曹彬教授讲解项目内容。新华社记者 程敏 摄

瑞德西韦临床试验项目负责人、中日友好医院副院长曹彬教授，在武汉市金银潭医院召开的科技部应急攻关“瑞德西韦治疗2019新型冠状病毒感染研究”项目启动会上介绍，瑞德西韦是美国吉利德公司的在研药物，在前期的细胞和动物实验中均显示出对SARS冠状病毒、MERS冠状病毒有较好的抗病毒活性，国外已开展瑞德西韦针对埃博拉冠状病毒感染的临床试验。

Remdesivir is a drug developed by Gilead Sciences, an American pharmaceutical company, said Cao Bin, head of the drug's clinical trial program, at the conference held by the MOST at the Wuhan Jinyintan Hospital, central China's Hubei Province. The drug has shown good antiviral activity against SARS and MERS coronavirus in previous cell and animal experiments. Its clinical trials against Ebola infections have been conducted abroad. 

近日，我国学者报道瑞德西韦在细胞水平上对2019新型冠状病毒也有较好的活性。

In related domestic research, it has also shown fairly good antiviral activity against the 2019-nCoV at the cellular level, said Cao.

中国工程院副院长、中国医学科学院院长王辰院士在启动会上表示，各界对这一试验有期望，但有无效果，还需要等待严格的科学试验结果。瑞德西韦临床试验由中日友好医院、中国医学科学院药物研究所牵头，研究将在武汉金银潭医院等多家临床一线接诊新型冠状病毒感染肺炎患者的医院中进行，拟入组761例患者，采用随机、双盲、安慰剂对照方法展开。

A total of 761 patients have been enrolled in the trials, which will adopt a randomized, double-blind and placebo-controlled study method. The trials, led by the China-Japan Friendship Hospital and the Institute of Materia Medica under the Chinese Academy of Medical Sciences (CAMS), will be conducted in several hospitals in Wuhan, including the Wuhan Jinyintan Hospital. Hopes have been pinned on the drug, but we have to wait for results of its actual effectiveness in the clinical trials, said Wang Chen, vice president of the Chinese Academy of Engineering and president of the CAMS.


2月5日，中国工程院副院长、中国医学科学院院长王辰院士（右一）介绍项目情况。 新华社记者 程敏 摄

据中国日报网报道，1月底吉利德公司发布声明，表示瑞德西韦尚未获得进入任何国家市场的许可，药物的安全性和有效性还有待证实。

In a statement at the end of last month, Gilead said Remdesivir had not gained approval to enter the market in any country, and its safety and effectiveness had not yet been proven.

此前，中日友好医院曾对外介绍，该项临床研究计划的结束时间是4月27日。

综合来源：新华网，中国日报网，CGTN